RESUMEN
Autophagy is a host defensive mechanism responsible for eliminating harmful cellular components through lysosomal degradation. Autophagy has been known to either promote or suppress various cancers including colorectal cancer (CRC). KRAS mutation serves as an important predictive marker for epidermal growth factor receptor (EGFR)-targeted therapies in CRC. However, the relationship between autophagy and KRAS mutation in CRC is not well-studied. In this single-centre study, 92 formalin-fixed paraffin-embedded (FFPE) tissues of CRC patients (42 Malaysian Chinese and 50 Indonesian) were collected and KRAS mutational status was determined by quantitative PCR (qPCR) (n=92) while the expression of autophagy effector (p62, LC3A and LC3B) was examined by immunohistochemistry (IHC) (n=48). The outcomes of each were then associated with the clinicopathological variables (n=48). Our findings demonstrated that the female CRC patients have a higher tendency in developing KRAS mutation in the Malaysian Chinese population (p<0.05). Expression of autophagy effector LC3A was highly associated with the tumour grade in CRC (p<0.001) but not with other clinicopathological parameters. Lastly, the survival analysis did not yield a statistically significant outcome. Overall, this small cohort study concluded that KRAS mutation and autophagy effectors are not good prognostic markers for CRC patients.
Asunto(s)
Autofagia , Neoplasias Colorrectales , Proteínas Proto-Oncogénicas p21(ras)/genética , Autofagia/genética , Estudios de Cohortes , Neoplasias Colorrectales/genética , Femenino , Humanos , MutaciónRESUMEN
INTRODUCTION: Autophagy is a mechanism that degrades large damaged organelles and misfolded proteins to maintain the homeostasis in all cells. It plays double-faceted roles in tumourigenesis and prevention of various cancers. In our side observation of investigating the prognostic value of autophagy in colorectal cancer (CRC), we found high expression of autophagy proteins (LC3A, LC3B, and p62/SQSTM1) in the colonic ganglion cells. To our best understanding, this is the first paper reporting such finding. MATERIALS AND METHODS: Formalin-fixed paraffin-embedded (FFPE) CRC tissues blocks were retrieved and confirmed by haematoxylin & eosin (H&E) staining. Immunohistochemistry (IHC) targeting autophagy proteins (LC3A, LC3B, and p62/SQSTM1) was then performed followed by pathological examination. RESULTS: All three autophagy proteins were present in both normal and tumour tissues of CRC patients. Interestingly, high expression of autophagy proteins in colonic ganglion cells was consistently seen regardless of tissue type (normal or cancer) or tumour site (caecum, ascending, transverse, descending, sigmoid colon and rectum). CONCLUSIONS: This work highlights the high autophagic activities in human colonic ganglion cells.
Asunto(s)
Autofagia/fisiología , Colon/metabolismo , Neuronas/metabolismo , Neoplasias Colorrectales/metabolismo , Humanos , Proteínas Asociadas a Microtúbulos/metabolismo , Proteína Sequestosoma-1/metabolismoRESUMEN
INTRODUCTION: Epstein-Barr Virus (EBV) is associated with several B-cell non-Hodgkin's lymphoma (NHL), but the role of EBV in diffuse large B-cell lymphoma (DLBCL) is poorly defined. Several studies indicated the expression of phosphorylated STAT3 (pSTAT3) is predominant in EBV(+)- DLBCL, of which its activated form can promote the downstream oncogenes expression such as c-MYC. c-MYC gene rearrangements are frequently found in aggressive lymphoma with inferior prognosis. Furthermore, EBV is a co-factor of MYC dysregulation. JAK1/STAT3 could be the downstream pathway of EBV and deregulates MYC. To confirm the involvement of EBV in JAK1/ STAT3 activation and MYC deregulation, association of EBV, pSTAT3 and MYC in EBV(+)- DLBCL cases were studied. The presence of pSTAT3 and its upstream proteins: pJAK1 is identify to delineate the role of EBV in JAK1/STAT3 pathway. MATERIALS AND METHODS: 51 cases of DLBCL paraffin-embedded tissue samples were retrieved from a single private hospital in Kuala Lumpur, Malaysia. EBER-ISH was performed to identify the EBV expression; ten EBV(+)-DLBCL cases subjected to immunohistochemistry for LMP1, pJAK1, pSTAT3 and MYC; FISH assay for c-MYC gene rearrangement. RESULTS: Among 10 cases of EBV(+)-DLBCL, 90% were non-GCB subtype (p=0.011), 88.9% expressed LMP1. 40% EBV(+)-DLBCL had pJAK1 expression. CONCLUSION: 66.7% EBV(+)-DLBCL showed the positivity of pSTAT3, which implies the involvement of EBV in constitutive JAK/STAT pathway. 44.5% EBV(+)-DLBCL have co-expression of pSTAT3 and MYC, but all EBV(+)-DLBCL was absence with c-MYC gene rearrangement. The finding of clinical samples might shed lights to the lymphomagenesis of EBV associated with non-GCB subtypes, and the potential therapy for pSTAT3-mediated pathway.
Asunto(s)
Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/patogenicidad , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/virología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Inmunohistoquímica/métodos , Janus Quinasa 1/metabolismo , Malasia , Masculino , Persona de Mediana Edad , Pronóstico , Factor de Transcripción STAT3/metabolismoRESUMEN
INTRODUCTION: Epstein-Barr virus (EBV) might be an aetiological agent involved in the pathogenesis of certain Non-Hodgkin's Lymphomas (NHLs). EBV infection has been diagnosed by serologic testing within the tumour biopsies of patients with NHL. However, the association between EBV and NHL is inconsistent with a preference for certain anatomic sites, histologic subtypes and immunosuppressed patients. The objective of this study was to characterise the B-cell NHLs of the oral cavity and maxillofacial region using histological and immunophenotypical techniques and to determine its association with EBV infection. MATERIALS AND METHODS: This was a descriptive cross-sectional study that included 14 cases of B-cell NHLs of the oral cavity and maxillofacial region. The haematopoietic and lymphoid tissue tumours classification of WHO was used to categorize the cases. In-situ hybridisation for EBV-encoded RNA was performed to confirm the EBV infection. RESULTS: The average age of the patients included in the study was found to be 48.8 ± 23 years with a higher female to male ratio (1.3:1). Our study suggested that diffuse large B-cell lymphomas (DLBCLs) and Burkitt's lymphomas (BLs) constitute the predominant subtypes of lymphomas affecting the oral cavity and maxillofacial regions. CONCLUSION: The findings from our study support the view that at least a relatively smaller proportion of B-cell NHLs that occur in the oral cavity and maxillofacial region do not have a pathogenic association with EBV.
Asunto(s)
Infecciones por Virus de Epstein-Barr/epidemiología , Linfoma de Células B/virología , Neoplasias de la Boca/virología , Adolescente , Adulto , Anciano de 80 o más Años , Niño , Estudios Transversales , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana EdadRESUMEN
Malignant transformation from normal colonic mucosa to carcinomas may be accelerated by genetic loss or inactivation of genes of the DNA mismatch repair system. The aim of the study was to determine the local incidence and pattern of immunohistochemical expression of mismatch repair proteins namely: hMLH1, hMSH2 and hMSH6 in a series of colorectal carcinomas (CRCs) and correlate this to their clinical and pathological features. Forty-three out of 298 cases of CRCs (14.4%) showed abnormal staining pattern for mismatch repair proteins with a majority (65.1%) showing single hMLH1 loss. Tumours with mismatch repair defect (MMR-d) were frequently found at the right side of colon (p<0.001), poorly differentiated carcinomas (p<0.001), produced more mucin (p=0.007), exophytic growth (p=0.007) and were bigger (p=0.002) than tumours with no mismatch repair defect. Immunohistochemical stains for mismatch repair proteins could be done in local laboratories on these selected cases before referring for the expensive molecular test.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/biosíntesis , Biomarcadores de Tumor/análisis , Carcinoma/metabolismo , Neoplasias Colorrectales/metabolismo , Proteínas de Unión al ADN/biosíntesis , Proteína 2 Homóloga a MutS/biosíntesis , Proteínas Nucleares/biosíntesis , Proteínas Adaptadoras Transductoras de Señales/análisis , Carcinoma/mortalidad , Carcinoma/patología , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Proteínas de Unión al ADN/análisis , Femenino , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Malasia , Masculino , Persona de Mediana Edad , Homólogo 1 de la Proteína MutL , Proteína 2 Homóloga a MutS/análisis , Proteínas Nucleares/análisisRESUMEN
Amyloidosis of the skull base is a rare entity. A patient with localized amyloidosis of the sphenoid sinus presented at our institution with cerebrospinal fluid rhinorrhoea. Endoscopic excision of the lesion and multilayered obliteration of the sphenoid sinus resolved the symptoms.
Asunto(s)
Amiloidosis/complicaciones , Rinorrea de Líquido Cefalorraquídeo/etiología , Enfermedades de los Senos Paranasales/complicaciones , Seno Esfenoidal , Amiloidosis/cirugía , Humanos , Masculino , Persona de Mediana Edad , Enfermedades de los Senos Paranasales/cirugíaRESUMEN
Diffuse large B-cell lymphoma (DLBCL) is a heterogenous entity. The pattern of CD15, CD30 and Bcl-2 expression is not well documented, especially in local population. We investigated 67 consecutive cases of DLBCL by immunohistochemistry on paraffin-embedded tissue. The male to female ratio was 1.2:1 with median age of 55 years, and more common nodal than extranodal in presentation. Only 3 of 67 cases expressed CD15. In addition, three cases showed weak membrane staining for CD30. Only one of these three cases was noted to have co-expression of CD15 and with occasional tumour cells showing weak CD30 expression. Bcl-2 protein was expressed in 43 of 67 (64%), more frequently in nodal than in extranodal tumours. In conclusion, CD15 and CD30 expressions are infrequent in DLBCL, and co-expression is rare. Bcl-2 protein expression is common in DLBCL.
Asunto(s)
Genes bcl-2/genética , Antígeno Ki-1/biosíntesis , Antígeno Lewis X/biosíntesis , Linfoma de Células B/genética , Linfoma de Células B Grandes Difuso/genética , Proteína X Asociada a bcl-2/biosíntesis , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/metabolismo , Niño , Femenino , Humanos , Inmunohistoquímica , Antígeno Ki-1/genética , Antígeno Lewis X/genética , Linfoma de Células B/metabolismo , Linfoma de Células B Grandes Difuso/metabolismo , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Proteína X Asociada a bcl-2/genéticaRESUMEN
Gastrointestinal stromal tumour (GIST) is a rare but most common mesenchymal tumour in the gastrointestinal tract. Although GIST research has been carried out extensively worldwide, it has yet to be studied in Malaysia. To establish the immunohistochemical expression pattern of CD117 (c-KIT), CD34, S-100 and Desmin, the incidence of c-KIT and PDGFRA genes mutation in GISTs, and correlate it with clinicopathological parameters. Eleven clinically diagnosed GISTs were stained for CD117, CD34, Desmin and S-100 protein by immunohistochemical technique, and c-KITand PDGFRA gene mutations were studied by PCR-CSGE-DNA sequencing method. All GISTs (7 cases) stain positive for CD117, and co-expressed CD34. None of these cases express Desmin, and only one expressed S-100 protein focally. Fifty-seven percent (4/7 cases) of GIST harboured mutations at exon 11 of c-KIT gene, and they were all high risk and malignant cases. No mutation was detected at exons 9, 13 and 17 of KIT gene, and exons 12 and 18 of PDGFRA gene. Immunohistochemistry using a panel of antibodies shows consistent pattern of CD117 and CD34 expression in GIST, and mutational study may be a useful prognostic marker for kinase inhibitor treatment of GIST.
Asunto(s)
Tumores del Estroma Gastrointestinal/diagnóstico , Adulto , Anciano , Secuencia de Bases , Análisis Mutacional de ADN , Femenino , Tumores del Estroma Gastrointestinal/genética , Tumores del Estroma Gastrointestinal/inmunología , Tumores del Estroma Gastrointestinal/patología , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Mutación , Proteínas Proto-Oncogénicas c-kit/genética , Receptor alfa de Factor de Crecimiento Derivado de Plaquetas/genéticaRESUMEN
BACKGROUND: Recent reports have divided diffuse large B cell lymphoma (DLBCL) into germinal centre B cell-like and activated B cell-like subgroups with implicated differences in prognosis. AIMS: To delineate the germinal centre B cell derivation group from an Asian series of DLBCLs. METHODS: Fifty four cases were analysed by polymerase chain reaction to detect the t(14;18) translocation and immunohistochemistry for BCL2, CD10, BCL6, and E2F1 expression. RESULTS: Eighteen of 54 cases had bcl2 gene rearrangement, 36 of 52 expressed BCL2, 29 of 52 expressed BCL6, 20 of 53 expressed CD10, and 18 of 53 expressed E2F1. There was a significant association between bcl2 gene rearrangement and the expression of both BCL2 and CD10. Using the minimally acceptable criteria of t(14;18) rearrangement and/or CD10 expression, 26 of 54 cases were probably germinal centre derived, in agreement with other reports. A higher proportion of cases had t(14;18) translocation, suggesting that they may be derived from transformed follicular lymphomas. E2F1 positivity did not correlate with the known germinal centre markers, even though it has recently been suggested that it may be a new GC marker. CONCLUSIONS: It may be possible to stratify patients for treatment using markers for specific lineages of B cell differentiation.
Asunto(s)
Centro Germinal/patología , Linfoma de Células B/patología , Linfoma de Células B Grandes Difuso/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Pueblo Asiatico/genética , Niño , Cromosomas Humanos Par 14/genética , Cromosomas Humanos Par 18/genética , Femenino , Reordenamiento Génico de Linfocito B , Genes bcl-2/genética , Humanos , Inmunofenotipificación , Linfoma de Células B/genética , Linfoma de Células B/inmunología , Linfoma de Células B Grandes Difuso/genética , Linfoma de Células B Grandes Difuso/inmunología , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Translocación GenéticaRESUMEN
AIM: To gain more insight into the genes involved in the aetiology and pathogenesis of anaplastic large cell lymphoma (ALCL). METHODS: Serial analysis of gene expression (SAGE) was undertaken on the CD4+ALK+ (anaplastic lymphoma kinase positive) ALCL derived cell line Karpas299 and as comparison on CD4+ T cells. Quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were performed on five ALCL derived cell lines and 32 tissue samples to confirm the SAGE data. RESULTS: High expression of Mcl-1 was seen in the Karpas299 cell line, whereas the two other antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-X(L), were not detected in the SAGE library. Quantitative RT-PCR confirmed the high expression of Mcl-1 mRNA and low expression of Bcl-2 and Bcl-X(L) in Karpas299 and in four other ALCL cell lines. To expand on these initial observations, primary tissue samples were analysed for Mcl-1, Bcl-X(L), and Bcl-2 by immunohistochemistry. All 23 ALK+ and nine ALK- ALCL cases were positive for Mcl-1. Bcl-2 and Bcl-X(L) were expressed infrequently in ALK+ ALCL cases, but were present in a higher proportion of ALK- ALCL cases. CONCLUSION: The consistent high expression of Mcl-1 in ALK+ and ALK- ALCL suggests that Mcl-1 is the main antiapoptotic protein in this disease. The high frequency of Mcl-1, Bcl-2, and Bcl-X(L) positive ALCL cases in the ALK- group compared with the ALK+ group indicates that ALK induced STAT3 activation is not the main regulatory pathway in ALCL.
Asunto(s)
Regulación Neoplásica de la Expresión Génica/genética , Linfoma de Células B Grandes Difuso/genética , Proteínas de Neoplasias/genética , Proteínas Tirosina Quinasas/genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , Quinasa de Linfoma Anaplásico , Apoptosis/genética , Linfocitos T CD4-Positivos/fisiología , Línea Celular Tumoral , Genes bcl-2/genética , Humanos , Inmunohistoquímica/métodos , Proteína 1 de la Secuencia de Leucemia de Células Mieloides , ARN Mensajero/genética , ARN Neoplásico/genética , Proteínas Tirosina Quinasas Receptoras , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Proteína bcl-XRESUMEN
AIM: Tumour suppressor gene p53 is a common target in carcinogenesis, reported to be altered and functionally inactive in 70% of human cancers. Although p53 mutations are less commonly present in haematological malignancies when compared with other solid tumours, they have been reported in histological transformation of follicular lymphoma. We aimed to investigate the frequency of p53 gene alterations in paraffin-embedded tissue using commercially available PCR-SSCP, and to correlate the results with P53 protein expression by immunohistochemistry. METHODS: Surgical samples from seven patients with a total of 17 sequential biopsies were retrieved for the study of p53 gene expression using immunohistochemical stain, and gene status by PCR-SSCP for exons 5-8. The tumours were graded according to the WHO classification criteria. P53 was distinctly over-expressed in five transformed higher grade biopsies, and all except one showed electrophoretic mobility shift in PCR-SSCP analysis. Sequencing analysis revealed single nucleotide substitutions in three of four of these high-grade transformed cases with band shift (75%), whereas some other studies reported a lower frequency of 25-30%, and mobility shift result was found to correlate with P53 expression. Lower grade tumours without P53 over-expression did not demonstrate band shift, and sequencing analysis did not reveal mutations. CONCLUSIONS: We demonstrated the feasibility of adopting PCR-SSCP for screening of p53 mutations in archival tissue samples in this study, and there is a strong correlation of p53 gene over-expression and mutation events in high-grade transformed tumours.
Asunto(s)
Linfoma Folicular/genética , Linfoma Folicular/metabolismo , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Adulto , Anciano , Pueblo Asiatico , Femenino , Expresión Génica , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Mutación , Adhesión en Parafina , Reacción en Cadena de la Polimerasa , Polimorfismo Conformacional Retorcido-SimpleRESUMEN
Thymus and activation-regulated chemokine (TARC) has been identified as a lymphocyte-directed CC chemokine that attracts activated T-helper type 2 (Th2) cells in humans. Recent studies showed that the T cells surrounding Reed-Sternberg cells in Hodgkin's lymphomas (HL) are Th2 type. Anaplastic large cell lymphomas (ALCL), T-cell-rich B-cell lymphoma (TCRBCL) can mimic HL in some instances. This study aimed to establish the pattern of TARC expression in these diseases. Immunohistochemical stain using a polyclonal goat anti-human antibody to TARC was performed on 119 cases of confirmed HL; 99 were classical type (43 mixed cellularity, 43 nodular sclerosis, 5 lymphocyte depleted, 4 lymphocyte rich, 4 unclassifiable) and 20 lymphocyte predominant HL. Additional 27 ALCL (9 T-, 18 null-cell phenotype), 16 T-cell and 8 B-cell non-Hodgkin's lymphoma (NHL) were studied. A total of 85.8% of the classical HL, one case of ALCL, and one case of large cell B-cell lymphoma with anaplastic morphology showed positive TARC expression in the tumor cells. The expression was paranuclear and/or diffuse in the cell cytoplasm. The tumor cells in all cases of lymphocyte predominant HL, TCRBCL, null ALCL, and T-NHL did not express TARC. The high frequency of TARC expression in the Reed-Sternberg cells of classical HL may explain the characteristic T-cell infiltrate in this disease. The absence in other types that may be morphologically similar indicates that staining for TARC may aid in differential diagnosis.
Asunto(s)
Quimiocinas CC/metabolismo , Enfermedad de Hodgkin/metabolismo , Linfoma de Células B/metabolismo , Linfoma de Células B Grandes Difuso/metabolismo , Linfocitos T/patología , Quimiocina CCL17 , Diagnóstico Diferencial , Herpesvirus Humano 4/aislamiento & purificación , Humanos , Inmunohistoquímica , Linfoma de Células B/patología , Linfoma de Células B/virología , Linfoma de Células B Grandes Difuso/patología , Linfoma de Células B Grandes Difuso/virología , Células de Reed-Sternberg/metabolismoRESUMEN
OBJECTIVES: To determine the reinfection rate of Helicobacter pylori and duodenal ulcer relapse rate in a group of patients followed up long term. DESIGN: Prospective study. PATIENTS AND METHODS: Patients were followed up endoscopically at 3, 6, 12 and 24 months after successful H. pylori eradication and duodenal ulcer healing. H. pylori status was determined by culture, rapid urease test, Gram's stain of a fresh tissue smear and histological examination of antral biopsies and rapid urease test and histological examination of corpus biopsies. MAIN OUTCOME MEASURES: Duodenal ulcer healing, H. pylori reinfection. RESULTS: Thirty-eight patients with duodenal ulcer disease (35 active, 3 healed) had successfully eradicated H. pylori following treatment with omeprazole/amoxycillin (n = 11), omeprazole/amoxycillin/metronidazole (n = 16) and colloidal bismuth subcitrate/ amoxycillin/metronidazole (n = 11). All patients with active duodenal ulcer had healed ulcers at the end of therapy. Thirty-five of 38 patients were seen according to schedule up to 2 years; two patients were seen up to 12 months and one up to 6 months only. Reinfection with H. pylori was not recorded in any of our patients. Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H. pylori status was negative in all three. Subsequent follow-up revealed spontaneous healing of the ulcers in all three patients. At 2 years, one patient whose H. pylori status was negative had recurrence of duodenal ulcer. All of the three patients who defaulted subsequent to follow-up were negative for H. pylori and had healed ulcers on follow-up endoscopy at 6 and 12 months. CONCLUSION: Reinfection rate with H. pylori was zero in a group of South-East Asian patients who had successfully eradicated the infection. Duodenal ulcer relapse was also low (2.9%) in this group of patients at 2 years.
Asunto(s)
Úlcera Duodenal/epidemiología , Úlcera Duodenal/microbiología , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Amoxicilina/uso terapéutico , Antiulcerosos/uso terapéutico , Bismuto/uso terapéutico , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Infecciones por Helicobacter/tratamiento farmacológico , Humanos , Malasia/epidemiología , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Omeprazol/uso terapéutico , Compuestos Organometálicos/uso terapéutico , Penicilinas/uso terapéutico , Estudios Prospectivos , Recurrencia , Factores de TiempoRESUMEN
OBJECTIVE: To determine whether duodenal ulcers continue to heal following successful Helicobacter pylori eradication with short-term eradication therapy without further acid suppression therapy. METHODS: Patients with endoscopically proven duodenal ulcers who were H. pylori positive were randomized to receive omeprazole 40 mg each morning and clarithromycin 500 mg three times daily or famotidine 40 mg twice daily and clarithromycin 500 mg three times daily for 2 weeks. No acid-suppressing agents nor ulcerhealing drugs such as bismuth compounds or sucralfate were prescribed after that. Patients were re-examined endoscopically at week 2 at the end of treatment, and at week 6, 4 weeks after the completion of treatment. RESULTS: Thirty of 44 (68.2%) patients from both treatment arms, in whom the bacteria were subsequently noted to have been eradicated, had healed ulcers at week 2; at Week 6, 42 of 44 (95.5%) were noted to have healed ulcers without further acid-suppressing or ulcer-healing treatment. CONCLUSION: Although a short-term acid-suppressing treatment is insufficient to heal ulcers, where an important putative factor such as H. pylori is eliminated, the ulcer healing process continues without further need for acid-suppressing or ulcer-healing agents.
Asunto(s)
Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Úlcera Duodenal/tratamiento farmacológico , Úlcera Duodenal/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Adulto , Anciano , Claritromicina/uso terapéutico , Quimioterapia Combinada , Famotidina/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Omeprazol/uso terapéutico , Inhibidores de la Bomba de Protones , Resultado del Tratamiento , Cicatrización de HeridasRESUMEN
A hitherto undescribed group of lesions consisting of cystic bony lesions, exostosis, fibromatous lesion, unilateral tonsillar hypertrophy, epidermoid cyst (cholesteatoma) and hyperplasia of the mandible confined to the left side of the face is reported. The case may represent a variant of the Proteus syndrome.
Asunto(s)
Quistes Óseos , Colesteatoma , Exostosis , Huesos Faciales , Apófisis Mastoides , Adulto , Diagnóstico Diferencial , Síndrome de Gardner , Humanos , Masculino , SíndromeRESUMEN
BACKGROUND: 47 patients with non-Hodgkin's lymphoma (NHL) were studied retrospectively to determine their marrow and blood changes at diagnosis. METHODS: The blood counts, blood films, marrow smears, trephine and tissue biopsies of patients at diagnosis were reviewed. The scheme proposed by the International Lymphoma Study Group (REAL) was utilised for lymphoma subclassification. RESULTS AND CONCLUSION: 21.3% had lymphoblastic lymphoma, 21.3% had peripheral T-cell lymphoma (unspecified), 29.8% had diffuse large B-cell NHL, 10.6% had Burkitt's lymphoma and 17% had others. The incidences of anaemia, one or more abnormal counts, lymphocytopenia, increased marrow reticulin and marrow eosinophilia at diagnosis were 66%, 85.1%, 41.3%, 40.9% and 44.7% respectively. Marrow involvement was present in 46.8% of the patients, with diffuse infiltration noted in 71.4% of these cases. Abnormal counts and anaemia were common in all the NHL subtypes. In lymphoblastic lymphoma, the common haematological abnormalities were peripheral atypical lymphocytes and diffuse marrow involvement. In peripheral T-cell lymphoma (unspecified), common features were peripheral lymphocytopenia, increased marrow reticulin and eosinophilia. In diffuse large B-cell NHL, peripheral lymphocytopenia, peripheral myeloid precursors and/or nucleated red cells and marrow involvement were common. In Burkitt's lymphoma, diffuse marrow involvement and eosinophilia were common. No significant differences were noted between most of the haematological parameters of B and T-NHLs. In comparison with other reports, we recorded higher overall incidences of anaemia and diffuse marrow involvement, and a lower incidence of marrow infiltration in peripheral T-cell lymphoma (unspecified).
Asunto(s)
Médula Ósea/patología , Linfoma no Hodgkin/sangre , Linfoma no Hodgkin/patología , Anemia/etiología , Biopsia , Recuento de Células Sanguíneas , Examen de la Médula Ósea , Humanos , Incidencia , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/epidemiología , Linfopenia/etiología , Estudios Retrospectivos , Trombocitopenia/etiologíaRESUMEN
INTRODUCTION: T- and B-lymphocytes are involved in recognition of foreign antigen by the specificity of their surface T-cell receptor and immunoglobulin, generated by gene rearrangement. Each T- and B-lymphocyte carries unique rearranged TCR or immunoglobulin gene, which has been applied to detect clonal from non-clonal T- and B-cell proliferation. METHODS: Paraffin-embedded biopsy tissues of 85 T-, 24 B-cell non-Hodgkin's lymphomas (NHL) of various subtypes, and seven reactive lymphoid hyperplasia were retrieved from the archives for determining the feasibility of TCRgamma gene rearrangement analysis by PCR assays in our laboratory. DNA was extracted by Proteinase K digestion. The analyses were performed by five PCR assays, and analysed on polyacrylamide gel. RESULTS: Clonal TCRgamma gene rearrangement was demonstrated in 69/85 (81.2%) of the cases. Selective rearrangement of specific Vgamma segment was observed, especially in peripheral T-cell lymphoma-unspecified and nasal NK/T-cell lymphoma. Clonal TCRgamma rearranged band was also demonstrated in 4/24 (16.7%) and 2/7 (28.6%) of B-NHL and reactive lymphoid tissues respectively. CONCLUSION: PCR assays were able to demonstrate clonal TCRgamma gene rearrangement in a high proportion of T-NHL. However, the PCR results should be interpreted carefully. A neoplasm should only be considered as T-cell type if it does not express any B-cell marker because TCRgamma is not lineage specific as shown by the presence of clonal TCRgamma gene rearrangement in B-NHL. Hence, the results for TCR gene rearrangement should always be interpreted in conjunction with histology and immunophenotyping.
Asunto(s)
Linaje de la Célula/genética , Reordenamiento Génico de la Cadena gamma de los Receptores de Antígenos de los Linfocitos T , Linfoma no Hodgkin/genética , Reacción en Cadena de la Polimerasa/métodos , Linfocitos T/inmunología , Linfocitos B/patología , ADN de Neoplasias/análisis , Electroforesis en Gel de Poliacrilamida , Estudios de Factibilidad , Genes de Inmunoglobulinas , Humanos , Técnicas para Inmunoenzimas , Linfoma no Hodgkin/inmunología , Linfoma no Hodgkin/patología , Adhesión en Parafina , Receptores de Antígenos de Linfocitos T gamma-delta/genética , Sensibilidad y Especificidad , Linfocitos T/patología , Fijación del TejidoRESUMEN
BACKGROUND: Castleman's disease is an uncommon disease and the histopathogenesis is poorly understood. This study aims to investigate their clinicopathological and immunophenotypic profile. MATERIALS AND METHODS: Castleman's disease was reconfirmed in biopsy tissue from 10 patients in a period of 17 years. Immunohistochemical staining was performed on the archival materials, with antibodies to lymphoid antigens and oncogene products, Bcl-6 and Bcl-2. Six reactive hyperplastic lymph nodes and three tonsils were used for comparative study of the phenotypic expression. RESULT: There were three cases of plasma-cell and seven of hyaline-vascular variant. The ages of patients ranged from eight to 60 years (median 30 years). The three patients with plasma-cell variant were older, all females. Two of the plasma-cell variant had multicentric lesions associated with systemic disease. All patients with hyaline-vascular variant had localised disease. Atrophic follicle centres were present in all the diagnostic tissue of both subtypes, with loss of Bcl-6 follicular centre B-cells and presence of relatively few CD57 T-cells. These follicle centres stained strongly with anti-CD21. In the mantle zone, CD5 expression was observed in only two cases and Bcl-2 expression similar to reactive follicles was present in six. CONCLUSION: Loss of Bcl-6 B-cells in the atrophic follicle centres, characteristic CD21 network patterns, low rate of CD5 and Bcl-2 expression in the mantle-zone lymphocytes are present in both variants of Castleman's disease, differ distinctly from reactive follicles. The phenotypic similarity in these two variants suggests possibility of closely related pathogeneses.
Asunto(s)
Enfermedad de Castleman/patología , Inmunofenotipificación , Adolescente , Adulto , Antígenos CD/metabolismo , Enfermedad de Castleman/metabolismo , Niño , Proteínas de Unión al ADN/metabolismo , Femenino , Expresión Génica , Humanos , Hiperplasia , Inmunohistoquímica , Hibridación in Situ , Ganglios Linfáticos/patología , Linfocitos/metabolismo , Linfocitos/patología , Masculino , Persona de Mediana Edad , Tonsila Palatina/patología , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-6 , Factores de Transcripción/metabolismoRESUMEN
Omeprazole has been shown to have a suppressive effect on Helicobacter pylori. The aim of this study was to determine if prolonged treatment with omeprazole would result in a higher eradication rate than short course treatment. Twenty patients with endoscopy proven duodenal ulcers and unequivocal evidence of Helicobacter pylori (HP) infection based on culture, histology, urease test and Gram's stain of a fresh tissue smear were treated with omeprazole 40 mg om for 2-4 weeks. Following ulcer healing, patients received either maintenance omeprazole 20 mg om or placebo for up to one year. All 20 patients had healed ulcers following a 2-4 week course of omeprazole 40 mg om.. All were negative for HP at the end of treatment. Thirteen patients received short course therapy with omeprazole only, followed by placebo. On follow-up endoscopy at 3 months, only one of 13 (7.7%) had eradicated the bacteria. Seven patients received maintenance treatment with omeprazole 20mg om for one year. Following completion of treatment, patients were followed up at 1, 3 and 6 months. Only one of 7 (14.3%) patients had eradicated the infection on long term follow-up. The eradication rates of HP with both short and long course omeprazole monotherapy were low.
Asunto(s)
Antiulcerosos/administración & dosificación , Úlcera Duodenal/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori/efectos de los fármacos , Omeprazol/administración & dosificación , Adulto , Relación Dosis-Respuesta a Droga , Úlcera Duodenal/microbiología , Duodenoscopía , Femenino , Estudios de Seguimiento , Infecciones por Helicobacter/microbiología , Humanos , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Singapur , Resultado del TratamientoRESUMEN
With the increasing recognition of the importance of H. pylori in gastrointestinal disease, there is a need for a reliable, efficient and yet inexpensive diagnostic test. The performance of the rapid urease test (RUT) as an endoscopy suite diagnostic test was compared to the established methods of culture, histology and Gram stain of tissue smear, in 274 gastric biopsy samples. Histology had the highest sensitivity of 99.3% followed by the RUT (96.6%). Culture and Gram stain of tissue smear had 100% specificity, while the rapid urease test had 99.2% specificity. The RUT had a positive predictive value of 99.3% and a negative predictive value of 96.2%. The RUT is an inexpensive, rapid and reliable diagnostic test of H. pylori infection.